Sweden – Firefighting vehicles – Brandbil släckbil till Räddnngstjänsten Östra Kronoberg RÖK

The United States Marine Highway Program (USMHP), codified at 46 U.S.C. 55601, was originally established by Section 1121 of the Energy Independence and Security Act of 2007 to reduce landside congestion through the designation of Marine Highway Routes. The USMHP statute authorizes the U.S. Department of Transportation (“Department” or “DOT”) to make grants to implement Projects or components of Projects that 1) provide a coordinated and capable alternative to landside transportation; mitigate or relieve landside congestion; promote Marine Highway Transportation; or use vessels documented under 46 U.S.C. chapter 121; and 2) develop, expand, or promote Marine Highway Transportation or shipper use of Marine Highway Transportation

The Motor Carrier Safety Assistance Program (MCSAP) is a Federal formula grant program that provides financial assistance to States, and U.S. Territories to reduce the number and severity of crashes, injuries, and fatalities and hazardous material incidents involving commercial motor vehicles.

The Federal Transit Administration (FTA) announces the opportunity to apply for competitive awards totaling up to $10 million in Public Transportation Innovation Program (49 U.S.C. 5312) funds for the Fiscal Year (FY) 2026 Bus Safety, Accessibility, and Innovation Research Program under Assistance Listing Number 20.530. As required by Federal public transportation law, funds will be awarded competitively to up to two projects to develop and prototype innovative and widely deployable concepts that are intended to make existing and new buses safer for their operators and vulnerable road users, and safer and more accessible for their passengers. 

Italy – Motor vehicles – SETTORI SPECIALI - SOPRA SOGLIA COMUNITARIA – PROCEDURA APERTA PER LA STIPULA DI UN ACCORDO QUADRO PER IL NOLEGGIO A LUNGO TERMINE DI VEICOLI COMMERCIALI LEGGERI A RIDOTTO IMPATTO AMBIENTALE E A BASSO CONSUMO ENERGETICO DEL PARCO AUTOMEZZI DELLA SOCIETA’ CENTRIA SRL E DELLE ALTRE SOCIETA’ DI DISTRIBUZIONE GAS DEL GRUPPO ESTRA S.P.A.

HM Government of Gibraltar invites tenders for the supply and delivery of mid-size public service buses for use by the Gibraltar Bus Company Ltd. The Contracting Authority intends to purchase an initial six (6) vehicles following contract award, with the option to purchase additional vehicles during the contract period, up to a maximum aggregate quantity of twenty-four (24) vehicles over ten (10) years, subject to operational requirements, available funding and the terms of the Contract. Vehicles may be offered using electric, hybrid, HVO-compatible diesel or hydrogen fuel-cell electric propulsion and must comply fully with the technical, operational, accessibility, passenger-capacity and route-performance requirements contained in the Contract Documents. The requirement includes associated spare parts, consumables, diagnostic and specialist equipment, warranties, training, technical support and, where applicable, charging or refuelling infrastructure. The contract will be awarded to a single Economic Operator on the basis of the most economically advantageous tender. Evaluation will include life-cycle costs, vehicle quality and performance, passenger capacity and configuration, delivery timescales and environmental performance. Economic Operators must download and review all Request Documents and complete the online questionnaire and pricing document. Tender submissions, supporting evidence and all required attachments must be submitted electronically through the HM Government of Gibraltar Supplier Portal (https://hmgogsupplier.gibraltar.gov.gi/) by the deadline stated in this notice. Clarification requests must also be submitted through the portal's messaging facility. Additional information: Gibraltar does not participate in the Agreement on Government Procurement (GPA) under the World Trade Organization (WTO). HM Government of Gibraltar therefore reserves the right to consider only those bids from eligible tenderers in Gibraltar, the UK, or a country or territory covered by a trade agreement extending to Gibraltar that contains relevant procurement provisions.

Sweden – Building completion work – Byggarbeten kulturhistoriskt bestånd

Expected Impact: The action under this topic is expected to achieve the following impacts and contribute to the following EU policies/initiatives: deliver innovative, early technology solutions that contribute to addressing strategic unmet public health needs across multiple therapy areas to improve prevention, early diagnosis, and treatment; leverage the unique network and scale of IHI JU members to create a pipeline to support innovative startups in the health industry, fully integrated into European initiatives in support of start-ups and entrepreneurship; drive early cross-sector health R&D and innovation to strengthen the European healthcare industry’s global competitiveness, contributing to the EU Industrial Strategy and Pharmaceutical Strategy objectives; create a sustainable network of European healthcare incubators to guide and support highly talented and innovative early-stage companies; harness digital health and data-sharing technologies (e.g., AI and big data) to enable interoperable health solutions, contributing to the European Health Data Space (EHDS) and improved evidence based care;- the action should generate a portfolio of early‑stage companies that have…

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Outcome: This action will establish a strategic European initiative to develop scalable, modular, and interoperable photonic quantum computing platforms. Proposals for this topic are expected to address and provide credible solutions to at least two major technical roadblocks currently limiting the advancement of photonic quantum computing such as: The lack of deterministic, high-efficiency photonic entanglement and loss-tolerant architectures suitable for fault-tolerant scaling The absence of a standardised, integrated control stack combining photonic hardware, firmware, and system software with reliable benchmarking across platforms Project results are expected to contribute to the following expected outcomes: By 2028, demonstration of a photonic NISQ processor with ≥100 photonic qubits, integrating deterministic single-photon sources, low-loss waveguides, on-chip detectors, and a firmware stack (scheduler, controller, compiler), validated via hardware-agnostic benchmarks and hybrid photonic-HPC applications demonstrating classical-quantum crossover By 2030, delivery of a full-stack, high-connectivity photonic quantum computer, with modular scalability, integrated…

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…